A PYMNTS Company

EU: Commission clears $66 billion Actavis deal

By  |  March 16, 2015

Actavis and Allergan have cleared the last hurdle antitrust hurdle closing their $66 billion merger agreement.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The European Commission has signed off on the tie-up, the companies said Monday. And with that, they expect the acquisition to wrap up Tuesday, they said in a statement.

    While the drugmakers haven’t until now had all of their official OK’s to tie the knot, the integration process has been underway for awhile. Actavis quickly started rebranding the company as a “growth pharma”–to set it apart from the slow-growth Big Pharma companies it will join in the industry’s global top 10 when the deal closes.

     

    Full Content: The Wall Street Journal

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.